Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy

Authors

  • Takanori Sako From the Third Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan
  • Naoto Burioka From the Third Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan
  • Kazuhito Yasuda From the Third Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan
  • Katsuyuki Tomita From the Third Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan
  • Masanori Miyata From the Third Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan
  • Jun Kurai From the Third Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan
  • Hiroki Chikumi From the Third Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan
  • Masanari Watanabe From the Third Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan
  • Hisashi Suyama From the Third Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan
  • Yasushi Fukuoka From the Third Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan
  • Yasuto Ueda From the Third Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan
  • Eiji Shimizu From the Third Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan

DOI:

https://doi.org/10.1080/02841860310016226

Abstract

Paclitaxel is a new agent for advanced non-small cell lung cancer (NSCLC). Weekly doses may enhance antitumor activity while minimizing toxicity, but little is known about immune recovery. Paclitaxel (80 mg/m2) was administered to 10 patients with NSCLC, weekly during 3-week cycles. Natural killer (NK) activity, CD3−CD16+CD56+ NK cells, and differential counts were monitored. NK activity appeared in all patients after treatment with paclitaxel therapy. NK activity showed a 27±9% decrease (mean±SE) on protocol day 8 and a 37±7% decrease on day 15 (p<0.05) recovering to 89±5% of baseline on day 29. With weekly paclitaxel, a decrease in NK cell function persisted through the first cycle but then recovered. Weekly paclitaxel may be less immunosuppressive than agents such as cisplatin.

Downloads

Download data is not yet available.

Downloads

Published

2004-03-01

How to Cite

Sako, T. . ., Burioka, N. . ., Yasuda, K. . ., Tomita, . K. . ., Miyata, M. . ., Kurai, J. . ., … Shimizu, E. . . (2004). Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy. Acta Oncologica, 43(1), 15–19. https://doi.org/10.1080/02841860310016226

Issue

Vol. 43 No. 1 (2004): Acta Oncologica

Section

Articles